Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
38
CLRB Quote, Financials, Valuation and Earnings
Last price:
$0.26
Seasonality move
:
-2.17%
Day range:
$0.25 - $0.28
52-week range:
$0.22 - $4.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
657.46x
P/B ratio:
6.75x
Volume:
795.7K
Avg. volume:
3.1M
1-year change:
-90.17%
Market cap:
$10.5M
Revenue:
--
EPS (TTM):
-$1.90
Analysts' Opinion
-
Consensus RatingCellectar Biosciences has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.67, Cellectar Biosciences has an estimated upside of 2135.37% from its current price of $0.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $0.25.
Fair Value
-
According to the consensus of 2 analysts, Cellectar Biosciences has 2135.37% upside to fair value with a price target of $5.67 per share.
CLRB vs. S&P 500
-
Over the past 5 trading days, Cellectar Biosciences has underperformed the S&P 500 by -6.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cellectar Biosciences does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cellectar Biosciences revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Cellectar Biosciences reported revenues of --.
Earnings Growth
-
Cellectar Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cellectar Biosciences reported earnings per share of -$0.40.
Enterprise value:
-10.2M
EV / Invested capital:
--
Price / LTM sales:
657.46x
EV / EBIT:
--
EV / Revenue:
767.39x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$27.3M | -$33.8M | -$51.6M | -$9.4M | -$13.3M | |
| EBITDA | -$27.2M | -$33.7M | -$51.3M | -$9.4M | -$13.3M | |
| Diluted EPS | -$4.46 | -$4.10 | -$1.90 | -$1.55 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.8M | $41.4M | $18.8M | $20.1M | $35.9M | |
| Total Assets | $20.7M | $42M | $19.3M | $21.6M | $37.3M | |
| Current Liabilities | $4M | $3.2M | $6.5M | $16.5M | $20.3M | |
| Total Liabilities | $4.5M | $3.4M | $6.6M | $34.9M | $22.1M | |
| Total Equity | $16.2M | $38.6M | $12.8M | -$13.4M | $15.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$22.3M | -$30.2M | -$46.3M | -$8.1M | -$9.2M | |
| Cash From Investing | -$237.9K | -$715.1K | -$309.7K | -$597.3K | -- | |
| Cash From Financing | -- | $32.1M | $61.9M | $22.5M | $17.6M | |
| Free Cash Flow | -$22.6M | -$30.9M | -$46.6M | -$8.7M | -$9.2M | |
CLRB
Sector
Market Cap
$10.5M
$45.6M
Price % of 52-Week High
5.7%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-90.17%
-31.35%
Beta (5-Year)
0.891
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.25
200-day SMA
Sell
Level
$2.45
Bollinger Bands (100)
Sell
Level
1.24 - 2.36
Chaikin Money Flow
Sell
Level
-104.8M
20-day SMA
Sell
Level
$0.85
Relative Strength Index (RSI14)
Sell
Level
9.90
ADX Line
Buy
Level
15.08
Williams %R
Buy
Level
-97.6698
50-day SMA
Sell
Level
$1.52
MACD (12, 26)
Sell
Level
-0.41
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Sell
Level
-21.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Stock Forecast FAQ
In the current month, CLRB has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CLRB average analyst price target in the past 3 months is $5.67.
-
Where Will Cellectar Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cellectar Biosciences share price will rise to $5.67 per share over the next 12 months.
-
What Do Analysts Say About Cellectar Biosciences?
Analysts are divided on their view about Cellectar Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cellectar Biosciences is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Cellectar Biosciences's Price Target?
The price target for Cellectar Biosciences over the next 1-year time period is forecast to be $5.67 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CLRB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cellectar Biosciences is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of CLRB?
You can purchase shares of Cellectar Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cellectar Biosciences shares.
-
What Is The Cellectar Biosciences Share Price Today?
Cellectar Biosciences was last trading at $0.26 per share. This represents the most recent stock quote for Cellectar Biosciences. Yesterday, Cellectar Biosciences closed at $0.25 per share.
-
How To Buy Cellectar Biosciences Stock Online?
In order to purchase Cellectar Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
